BioSniper
Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Par

November 1, 2027
Company
Harmony Biosciences Holdings, Inc. (HRMY)
Drug
hbs-301
Indication
Narcolepsy; Fatigue; Cataplexy

Other upcoming events for HRMY

Phase 2 ReadoutPhase 2 Readout: bp1.15205
Dec 31, 2026
Phase 3 ReadoutPhase 3 Topline: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydr
May 1, 2029
Phase 3 ReadoutPhase 3 Topline: Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Thera
Nov 1, 2029
Patent ExpiryPatent/Exclusivity Expiry: WAKIX
Jun 21, 2031

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
HRMY OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle